<unk>  is contraindicated in patients who have active infections, underlying immunodeficiency (e.g., seropositive for HIV), or known type I hypersensitivity or anaphylactic reactions to the substance.
Alemtuzumab
Ruxolitinib
Rituximab
Lenalidomide
Imatinib
Ibrutinib
Bosutinib
Ponatinib